ON DEMAND
Fresh from ASCO 2025: What Oncology Advancements Mean for Your Commercial Strategy
The Data Is In
ASCO 2025 delivered a wave of clinical insights - but how do you translate them into commercial action?
In this exclusive on-demand session, Diaceutics’ Chief Precision Medicine Officer Susanne Munksted and VP of Precision Medicine Strategy Kevin Entwistle unpack the most impactful developments from ASCO and and how they inform smarter go-to-market decisions, infrastructure planning, and precision patient engagement.
Speaker Bios
Copyright © 2024, Diaceutics. All rights reserved
DURATION
30 Minutes
FORMAT
Expert Conversation
SPEAKERS
Susanne Munksted & Kevin Entwistle
Access the Insights
Fill out the form to unlock the full 30-minute session and get practical takeaways to bring back to your team.
In 30 Minutes, you'll learn:
✅ The Data Is Clear: Commercial Strategy Must Drive Timely Testing Availability
Why trials like SERENA-6 and MATTERHORN are reshaping treatment strategies - and why commercial teams should care.
✅ ADCs Are Surging: Let’s Not Overcomplicate Diagnostics - Let’s Get Accuracy and Concordance Right
How the ADC pipeline boom is exposing new diagnostic challenges - and what commercial teams must do to prepare.
✅ From Monitoring to Milestones: How ctDNA Is Enabling Treatment Exit Decisions
What MONSTAR-SCREEN-3 and DYNAMIC-III reveal about ctDNA’s role in guiding therapy and expanding global access.
✅ Digital Pathology: Routine Clinical Adoption Is Lagging, but the Need Is Growing Urgent
Why AI and digital tools are becoming essential for identifying patients and enabling targeted therapy access.
✅ AI in Oncology: Keeping a Pulse on a Potential Future Reality
How artificial intelligence is reshaping commercial planning - and what pharma teams must do to stay ahead.
Susanne Munksted, Chief Precision Medicine Officer, Diaceutics
Susanne brings a wealth of experience to her role in leading a global team of precision medicine industry experts dedicated to enhancing the testing ecosystem to help patients capitalize on new breakthrough personalized medications. Susanne's journey in molecular pathology has been marked by notable achievements, including spearheading several global launches of companion diagnostic products. As a leading author of the Practice Gaps Study, Susanne played a pivotal role in identifying 7 key clinical Practice Gaps contributing to patient leakage, and her impactful contributions to the field have earned her a well-deserved place among the PharmaVoice 100 list of transformational leaders in life sciences.
Kevin Entwistle, VP of Scientific & Advisory Services, Diaceutics
Kevin Entwistle has over 15 years of experience working in the pharmaceutical industry and supporting global leaders to develop impactful commercialization strategies for the launch of precision medicines. He has previously worked for Qiagen, Leica Biosystems and J&J. Kevin’s expertise extends across multiple indications including oncology, neurology, immunology, cardiovascular and rare diseases. As VP of Scientific & Advisory Services at Diaceutics PLC, Kevin utilizes his extensive experience and Diaceutics’ real-world data to provide pharmaceutical and biotech customers with a deep understanding of the current precision medicine landscape and the strategic guidance required to successfully launch therapies to market, enhancing patient outcomes and driving the adoption of precision medicines.